ALK and anaplastic large cell lymphoma: Clinical trial (NCT05934045) aims to determine whether circRNAs can be used as prognostic and/or predictive biomarkers of Anaplastic lymphoma kinase (ALK) + Anaplastic large-cell lymphoma (ALCL) resistance to treatment.